NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced today the closing of its previously announced underwritten public offering of 4,531,434 shares of common stock of the Company, including the partial exercise by the underwriter of the option to purchase an additional 198,100 shares of common stock, at a price to the public of $0.75 per share.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The Company had granted to the underwriter a 30-day option to purchase up to an additional 650,000 shares of common stock at the public offering price, less underwriting discounts and commissions, of which the option to purchase an additional 198,100 shares of common stock has been exercised. The gross proceeds to NanoVibronix, before deducting underwriting discounts and commissions and offering expenses, including the partial exercise of the underwriter's option to purchase 198,100 additional shares of common stock, are approximately $3.4 million. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes, including for the transition of manufacturing of NanoVibronix's products from China to the United States.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company's primary products include PainShield®, UroShield® and WoundShield®, all of which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.